Postpartum Low-Dose Aspirin and Preeclampsia

{ "Postpartum Low-Dose Aspirin and Preeclampsia Study", "This study is looking at whether taking low-dose aspirin (81mg) after delivery can help improve blood vessel health in women who had severe preeclampsia. Preeclampsia is a serious condition during pregnancy that causes high blood pressure and can affect organs. The study will enroll about 100 women who had severe preeclampsia before delivery. You would be randomly assigned to take either low-dose aspirin or a placebo (an inactive pill) daily for up to three weeks after delivery. The main goal is to see if aspirin improves how well your blood vessels expand, which is measured by something called flow-mediated dilation (FMD). The study status is currently unclear.", "design": "This is an interventional study that plans to enroll about 100 women. Participants will be randomly assigned to receive either low-dose aspirin or a placebo.", "commitments": "You would take either low-dose aspirin (81mg) or a placebo oral capsule daily for up to 3 weeks post-delivery. Your blood vessel function (Flow-Mediated Dilation) will be measured up to 3 weeks postpartum.", "compensation": "Not stated in the trial record.", "follow_up": "Your blood vessel function will be measured up to 3 weeks postpartum.", }

Study design
Not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03667326

Postpartum Low-Dose Aspirin and Preeclampsia

Recruiting
PHASE2Ages 18+InterventionalPrevention
Columbia University
~100 participants
Updated 2026-01-22 on ClinicalTrials.gov
What's tested:Aspirin tabletPlacebo oral capsule

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Flow-Mediated Dilation (FMD)
Measured over Up to 3 weeks postpartum
Preeclampsia Postpartum
1 sites across 1 states
New York1
  • Aleha Aziz, MD, MPH · PRINCIPAL_INVESTIGATOR · Columbia University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Singleton or Multiple gestation
Maternal age \>= 18 years
20 0/7 weeks gestation or greater
Severe Preeclampsia diagnosed prior to delivery

Exclusion

Aspirin use postpartum for other medical indication
Lovenox, unfractionated heparin, or other anticoagulant use postpartum for an indication other than postoperative (in-house)
Aspirin use within 7 days of planned initial FMD testing postpartum
Hypersensitivity or allergy to Aspirin or other salicylates
Hypersensitivity or allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) - exception if taking LDA in pregnancy
Nasal polyps
Gastric or Duodenal ulcers, history of GI bleeding
Severe hepatic dysfunction
Bleeding disorders and diathesis
Breastfeeding a newborn with low platelets (NAIT)
  • Change in Flow-Mediated Dilation (FMD)Up to 3 weeks postpartum

    This is designed to measure if patients with preeclampsia with severe features diagnosed antepartum or intrapartum, will experience an increase in Flow-Mediated Dilation (FMD) - a measure of endothelial function - within 3 weeks after delivery when taking daily LDA in the postpartum period.